Levin Capital Strategies LP purchased $1.68M worth of shares in Fluidigm Corp. in June 2018
Jul 08, 2018
LCS follows a large-cap, bottom-up, value investment strategy. The firm invests client assets primarily in equity securities, of both domestic and foreign issuers that are traded on a US exchange. The firm invests client assets primarily in equity securities, of both domestic and foreign issuers that are traded on a US exchange. For their separately managed accounts, WRAP accounts, model portfolios and sub-advised funds following long-only strategies, LCS primarily invests in equity securities, ADRs/ADSs (including large foreign issuers whose ADRs/ADSs trade over-the counter), foreign equity securities traded on a foreign or a recognized US exchange, US Treasury obligations, corporate debt, warrants, convertible securities and exchange-traded funds. LCS utilizes a fundamental, bottom-up methodology to construct a managed account’s portfolio. The firm believes that the fundamental approach to select attractive long and short equity positions is the key to achieving sustained and substantial appreciation. They will typically engage in a detailed, bottom-up analysis of potential investments in evaluating potential investments. The funds also may utilize derivative instruments such as put and call options, SWAP or contracts for differences (CFD) transactions in particular securities, indices, SWAP baskets, futures contracts on market indices and put and call options on market indices in implementing its strategy.
In The News
Levin Capital Strategies LP disclosed in a filing on September 30, 2020 that it increased its stake in General Motors Company
Nov 23, 2020 - RelSci
Levin Capital Strategies LP disclosed a new stake in Brunswick Corporation in a filing on June 30, 2020
Aug 23, 2020 - RelSci
May 13, 2020 - Nasdaq
Fluidigm Corp. is engaged in the development, manufacture and marketing of biotechnology tools fro life sciences research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics; and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen R. Quake and Gajus V. Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.
In The News
Single-cell Analysis Market by Product, Cell Type, Technique, End User, and Geography - Global Forecast to 2026 - ResearchAndMarkets.com
Nov 23, 2020 - Business Wire
Nov 21, 2020 - GlobeNewswire